Actiste® receives positive ratings in user-experience research
Brighter AB (publ) (Bolaget) today announces positive results for Actiste® in user-experience research. In the 90-day user-experience research conducted at two health centers in Sweden, patients with insulin-treated type-2 diabetes and the healthcare workers treating them gave Actiste Diabetes Management as a Service (ADMS) positive ratings.
Brighter has published the results of Actiste® user-experience research conducted at two healthcare centers in Sweden. The insights were presented at the Diabetes Forum 2021 conference in Gothenburg on December 1-3. To read more about the results, click on the conference presentation page and scroll to “Poster 8”.
Key findings from the study include:
- 94% of patients rated the capability of ADMS to remind them to take insulin, identify missed insulin doses and increase their understanding of diabetes as “Excellent”, “Very good” or “Good”.
- 88% of patients also rated as “Excellent”, “Very good” or “Good” the capability of ADMS to engage them in their diabetes management.
- 82% of patients said they would recommend the service to a relative or friend with insulin-treated type-2 diabetes and rated ADMS as “Excellent”, “Very Good” or “Good”.
“We are very pleased and encouraged by the results and feedback received from the research. Clinical and user-experience insights of this nature are of strategic importance for Brighter, as we demonstrate how ADMS may contribute to the improvement of diabetes management”, says Dragan Zdravkovic, Head of Medical Affairs at Brighter.
“We would like to thank the research participants and the healthcare providers for their kind support, especially as it was challenging to organize and execute research during the Covid-19 pandemic”, says Zdravkovic.
For further information, please contact:
Investor Relations
IR@brighter.se
Certified Adviser
Brighter’s Certified Adviser is Eminova Fondkommission AB,
+46 (0)8 – 684 211 00, adviser@eminova.se, https://eminova.se/
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter’s quality management system is ISO-13485-certified. In 2019, the company won the Swecare Rising Stars Award. The company's shares are listed on Nasdaq First North Growth Market/BRIG. For more information, please visit our website via the following link: https://brighter.se/